Telephone
61.3.9692.7222
Address
Level 4 100 Albert Road South Melbourne, Victoria (VIC) 3205
Description
Prescient Therapeutics Ltd. is a biopharmaceutical company, which engages in the discovery and development of novel immunotherapeutic products for the treatment of chronic infectious diseases and cancer. It develops immune therapeutics based upon its Co-X-Gene and fowlpox virus delivery technologies. The company was founded on May 22, 1986 and is headquartered in South Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.05 - 0.16
Trade Value (12mth)
AU$16,328.00
1 week
23.29%
1 month
57.89%
YTD
-33.33%
1 year
-41.94%
All time high
184.854
EPS 3 yr Growth
14.300%
EBITDA Margin
N/A
Operating Cashflow
-$6m
Free Cash Flow Return
-28.90%
ROIC
-32.70%
Interest Coverage
N/A
Quick Ratio
12.20
Shares on Issue (Fully Dilluted)
762m
HALO Sector
Healthcare
Next Company Report Date
26-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.02
Date | Announcements |
---|---|
31 October 23 |
September 2023 Quarterly Update and Appendix 4C
×
September 2023 Quarterly Update and Appendix 4C |
31 October 22 |
September 2022 Quarterly Update and Appendix 4C
×
September 2022 Quarterly Update and Appendix 4C |
31 October 19 |
Prescient Ausbiotech Ras Presentation
×
Prescient Ausbiotech Ras Presentation |
31 January 22 |
December 2021 Quarterly Update and Appendix 4C
×
December 2021 Quarterly Update and Appendix 4C |
31 August 23 |
Section 708A Cleansing Notice
×
Section 708A Cleansing Notice |
31 August 23 |
Application for quotation of securities - PTX
×
Application for quotation of securities - PTX |
31 August 18 |
Appendix 4E and 2018 Annual Report
×
Appendix 4E and 2018 Annual Report |
31 August 16 |
Appendix 4E and 2016 Annual Report
×
Appendix 4E and 2016 Annual Report |
30 September 11 |
Virax Holdings Limited - Annual Report 30 June 2011 (VHL-AU)
×
Virax Holdings Limited - Annual Report 30 June 2011 (VHL-AU) |
30 September 10 |
Annual Report 2010 (VHL-AU)
×
Annual Report 2010 (VHL-AU) |
30 September 08 |
Virax Annual Report 2008
×
Virax Annual Report 2008 |
30 November 16 |
Results of Annual General Meeting
×
Results of Annual General Meeting |
30 August 21 |
Appendix 4E and 2021 Annual Report
×
Appendix 4E and 2021 Annual Report |
29 October 14 |
Virax Holdings Limited - Notice of Annual General Meeting/Proxy Form (VHL-AU)
×
Virax Holdings Limited - Notice of Annual General Meeting/Proxy Form (VHL-AU) |
29 November 22 |
Chair's Address to the 2022 Annual General Meeting
×
Chair's Address to the 2022 Annual General Meeting |
29 November 22 |
AGM Presentation
×
AGM Presentation |
29 November 22 |
Results of Annual General Meeting
×
Results of Annual General Meeting |
29 August 17 |
Appendix 4E and 2017 Annual Report
×
Appendix 4E and 2017 Annual Report |
29 April 22 |
March 2022 Quarterly Update and Appendix 4C
×
March 2022 Quarterly Update and Appendix 4C |
28 September 22 |
Extension of Share Purchase Plan
×
Extension of Share Purchase Plan |
28 September 07 |
Annual Report 2007 (VHL-AU)
×
Annual Report 2007 (VHL-AU) |
28 October 16 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
28 October 14 |
Virax Holdings Limited - Roadshow Presentation (VHL-AU)
×
Virax Holdings Limited - Roadshow Presentation (VHL-AU) |
28 November 23 |
Prescient Receives $2.4 Million R&D Tax Rebate
×
Prescient Receives $2.4 Million R&D Tax Rebate |
28 August 15 |
Prescient Appendix 4E and 2015 Annual Report
×
Prescient Appendix 4E and 2015 Annual Report |
28 April 23 |
March 2023 Quarterly Update and Appendix 4C
×
March 2023 Quarterly Update and Appendix 4C |
27 September 22 |
CellPryme-A Investor Presentation
×
CellPryme-A Investor Presentation |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.